IONIS PHARMACEUTICALS INC

For the period ended Mar 31, 2025. Filed Apr 30, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed Apr 30, 2025

IONS$28.19-9.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock · Additional · Accumulated Other · Accumulated · Total Stockholders’
Description	Shares	Amount	Paid in Capital	Comprehensive Loss	Deficit	Equity
Balance at December 31, 2023	144,341	$144	$2,215,098	$(32,645)	$(1,795,911)	$386,686
Net loss	—	—	—	—	(142,803)	(142,803)
Change in unrealized losses, net of tax	—	—	—	(2,205)	—	(2,205)
Foreign currency translation	—	—	—	(114)	—	(114)
Issuance of common stock in connection with employee stock plans, net	1,504	2	23,609	—	—	23,611
Stock-based compensation expense	—	—	31,340	—	—	31,340
Balance at March 31, 2024	145,845	$146	$2,270,047	$(34,964)	$(1,938,714)	$296,515
Balance at December 31, 2024	157,909	$158	$2,868,812	$(30,811)	$(2,249,808)	$588,351
Net loss	—	—	—	—	(146,938)	(146,938)
Change in unrealized gains, net of tax	—	—	—	1,630	—	1,630
Foreign currency translation	—	—	—	232	—	232
Issuance of common stock in connection with employee stock plans, net	1,132	1	2,241	—	—	2,242
Stock-based compensation expense	—	—	30,209	—	—	30,209
Balance at March 31, 2025	159,041	$159	$2,901,262	$(28,949)	$(2,396,746)	$475,726

Index

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.